Anna Ramos-Pachón, MD; David Rodríguez-Luna, MD, PhD; Joan Martí-Fàbregas, MD, PhD; et al.
free access
JAMA Neurol. 2023;80(10):1028-1036. doi:10.1001/jamaneurol.2023.2754
This prespecified secondary analysis of a randomized clinical trial conducted in Catalonia, Spain, assesses whether direct transport to an endovascular treatment鈥揷apable stroke center vs to the nearest local stroke center benefits patients experiencing intracerebral hemorrhage.
Ann C. McKee, MD; Jesse Mez, MD, MS; Bobak Abdolmohammadi, BA; et al.
open access
has audio
JAMA Neurol. 2023;80(10):1037-1050. doi:10.1001/jamaneurol.2023.2907
This cases series describes the neuropathologic and clinical features of young contact sport athletes who were younger than 30 years at the time of death.
-
Podcast:
Neuropathologic and Clinical Findings in Athletes With Repetitive Head Impacts
Alejandro Costoya-Sánchez, MSc; Alexis Moscoso, PhD; Jesús Silva-Rodríguez, PhD; et al.
open access
JAMA Neurol. 2023;80(10):1051-1061. doi:10.1001/jamaneurol.2023.2560
This cohort study examines the pathologic and cognitive changes in older individuals with tau deposition in the medial temporal lobe noted on positron emission tomography without evidence of amyloid-尾 pathology.
Robert A. Hauser, MD, MBA; Alberto J. Espay, MD; Aaron L. Ellenbogen, DO; et al.
open access
JAMA Neurol. 2023;80(10):1062-1069. doi:10.1001/jamaneurol.2023.2679
This randomized clinical trial evaluates the safety and efficacy of extended-release carbidopa-levodopa (IPX203) compared with immediate-release carbidopa-levodopa in patients with Parkinson disease.
Gisela Lilja, PhD; Susann Ullén, PhD; Josef Dankiewicz, PhD; et al.
open access
JAMA Neurol. 2023;80(10):1070-1079. doi:10.1001/jamaneurol.2023.2536
This study investigates the effects of targeted hypothermia vs targeted normothermia on functional outcome with focus on societal participation and cognitive function in survivors 6 months after out-of-hospital cardiac arrest.
Christine Lebrun-Frénay, MD, PhD; Aksel Siva, MD; Maria Pia Sormani, PhD; et al.
free access
JAMA Neurol. 2023;80(10):1080-1088. doi:10.1001/jamaneurol.2023.2815
This randomized clinical trial investigates the efficacy of the disease-modifying treatment, teriflunomide, in extending the time to a first clinical event in patients with preclinical multiple sclerosis.
Angela Genge, MD; Leonard H. van den Berg, MD, PhD; Glen Frick, MD, PhD; et al.
open access
JAMA Neurol. 2023;80(10):1089-1097. doi:10.1001/jamaneurol.2023.2851
This randomized clinical trial evaluates the safety and efficacy of the terminal complement C5 inhibitor ravulizumab vs placebo in adults with amyotrophic lateral sclerosis.
Lamiae Grimaldi, PharmD, PhD; Caroline Papeix, MD, PhD; Yann Hamon, BS; et al.
free access
JAMA Neurol. 2023;80(10):1098-1104. doi:10.1001/jamaneurol.2023.2968
This cohort study examines whether different vaccines are associated with multiple sclerosis flare-ups requiring hospitalization.
Ying Fu, PhD; Jin Bi, MD; Yaping Yan, PhD; et al.
free access
JAMA Neurol. 2023;80(10):1105-1112. doi:10.1001/jamaneurol.2023.2974
This case-control study investigates whether a rapid enzyme immunodot assay is equivalent to the gold standard cell-based assay for detecting immunoglobulin G autoantibodies against aquaporin 4 (AQP4) in patients with neuromyelitis optica spectrum disorder (NMOSD).